TIAA FSB’s Quest Diagnostics DGX Stock Holding History

TIAA FSB’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,290	Closed	-$202K	–	574
2022 Q4	$202K	Buy	+1,290	New	+$185K	﹤0.01%	543

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TIAA FSB's DGX Position: Q1 2023 in Review

TIAA FSB sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 1,290 shares — an estimated $202K sold.

TIAA FSB first reported a position in DGX in Q4 2022 and held it in 1 quarter. The position peaked at $202K in Q4 2022. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

TIAA FSB reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
TIAA FSB sold 1,290 Quest Diagnostics shares in Q1 2023, an estimated $202K.
TIAA FSB first reported a position in Quest Diagnostics in Q4 2022 and held it in 1 quarter.
TIAA FSB's Quest Diagnostics position peaked at $202K in Q4 2022.
834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on TIAA FSB's 13F filing for Q1 2023, filed 19 Apr 2023.